Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma has gained US patent covering Sitavig tablet, its manufacturing process and its application for the treatment of recurrent labial herpes until 2027.
Subscribe to our email newsletter
BioAlliance has developed Sitavig (mucoadhesive tablet containing acyclovir) for the treatment of labial herpes in immunocompetent patients presenting more than four episodes a year.
The mucoadhesive tablet should be applied to the upper gum, allowing the delivery of high concentrations of the active ingredient at the site of herpes infection.
BioAlliance Pharma European Patent Attorney and licensing and legal affairs vice president Aude Michel said, "After the grant of a patent for Sitavig in Europe and in major Asian territories, this US grant gives BioAlliance a worldwide protection for its product."
BioAlliance Pharma CEO Judith Greciet said the company obtained the receivability of Sitavig US registration file last May from the FDA (Food and Drug Administration).
"After a first license agreement with Teva for Israel and with a sales potential from $120 to $150 million, this product is becoming a suitable candidate to a license agreement, particularly in the United States," Greciet added.